PODXL and neoplasm: This signal is switched-on in both carcinoma and GBM cells by acquisition of a particular p53 mutation—p53R273H—which acts in combination with Rab35 to tune the PODXL content of tumor cell EVs into a range that influences ECM deposition by recipient cells—be they astrocytes or fibroblasts.